tbuckley/cabot-search huggingface dataset:
LEMUEL SHATTUCK (1793-1859) LAY ADVOCATE OF PUBLIC HEALTH
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smoking and Cancer
Journal: JAMA (1962)

<h3>To the Editor:—</h3> The article "Smoking Habits and Coronary Atherosclerotic Heart Disease (CAHD)" (<i>JAMA</i><b>177</b>:683-688 [Sept. 9] 1961) interested me greatly. Their Table 2 was: I would note first that the authors state that they had originally tabulated individuals according as they had smoked less than or more than 20 cigarettes daily but that, except for those smoking more than 40, there was no difference. This result is in noteworthy distinction from that found for mortality ratios by Hammond and Horn (<i>JAMA</i><b>166</b>: 1159-1172 [March 8] 1958) and (<i>JAMA</i><b>166</b>:1294-1308 [March 15] 1958), namely:which indicated that for deaths the ratio began to be really great in the one-half to one pack category. Admittedly, Spain's and Nathan's population is different from Hammond's and Horn's and cases are different from deaths, as they point out. Second, I will note that I cannot find in Fisher's work (quoted by Messrs. Spain and Nathan without specification) anything to justify marking the
Abstract 2330: MCT inhibition as a therapeutic strategy to target Enzalutamide-resistant prostate cancer
Journal: Cancer Research (2021)

Abstract Sayani Bhattacharjee, Jonathan Doan, Rebecca Wynn, Nagalakshmi Nadiminty Enzalutamide is a second-generation anti-androgen used for the treatment of prostate cancer. However, almost all patients develop resistance to this drug, thereby creating an urgent need of identifying new approaches that can overcome said resistance. Using parental and Enzalutamide-resistant C4-2B and 22RV1 cells, we targeted cellular metabolism to beat therapeutic resistance. Prostate cancers are more heterogeneous in their use of energy sources compared with other solid tumors and the most common metabolic end product is lactate, which is toxic to cancer cells upon accumulation. Hence, cancer cells upregulate the expression of monocarboxylate transporters (MCTs) that play a pivotal role in lactate efflux. Different MCT isoforms are differentially expressed across prostate cancer progression and presumably according to cellular demands at different stages. Gradual progression from benign prostate, to prostatic intraepithelial neoplasia, to in-situ carcinoma showed an increase in the expression of MCT2 and MCT4, with MCT4 being expressed in invasive prostate cancers. Based on our preliminary data that the expression of MCTs is higher in prostate cancer cells resistant to enzalutamide, we hypothesized that MCT inhibition may be an attractive therapeutic strategy against enzalutamide-resistant prostate cancer cells. Using cell survival, cell proliferation and clonogenic-ability assays, we found that the suppression of MCT activity using the MCT1/2 antagonists AR-C155858 or AZD3965 and the MCT 4 antagonist Syrosingopine not only diminishes the proliferation and survival of prostate cancer cells, but also re-sensitizes resistant cells to treatment with enzalutamide. We also found that treatment with AR-C155858 or AZD3965 either singly, or in combination with Enzalutamide suppressed prostate cancer cell xenograft growth in SCID mice bearing subcutaneously injected parental or Enzalutamide-resistant C4-2B cells. These findings imply that the MCTs have an intrinsic role in the acquisition of resistance to therapy. Citation Format: MCT inhibition as a therapeutic strategy to target Enzalutamide-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2330.
Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial James E. Tcheng, Mark Effron, Cindy L. Grines, Eulogio Garcia, David Cox, Thomas Stuckey, John Carroll, Giulio Guagliumi, Barry Rutherford, Alexandra J. Lansky, Paolo Esente, John Griffin, Gregg W. Stone. The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York City, NY, Duke University …
Journal: Journal of the American College of Cardiology (2001)
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Authors: P.G. Casali, P. Reichardt, Y. Kang, J. Blay, H. Joensuu, R.G. Maki, P. Rutkowski, P. Hohenberger, H. Gelderblom, M.G. Leahy, M. von Mehren, P. Schoffski, M.E. Blackstein, A. Le Cesne, G. Badalamenti, J. Xu, T. Nishida, D. Laurent, I. Kuss, G.D. Demetri
Journal: Annals of Oncology (2015)
Erratum for the Research Article: “Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis” by Y. Zhao, P. Gong, Y. Chen, J. C. Nwachukwu, S. Srinivasan, C. Ko, M. K. Bagchi, R. N. Taylor, K. S. Korach, K. W. Nettles, J. A. Katzenellenbogen, B. S. Katzenellenbogen
Journal: Science Translational Medicine (2015)
Two case reports by Richard Bright
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 6108: Cardiac 64-slice Multidetector Computerized Tomography in the Management of Prosthetic Heart Valve Obstruction
Authors: Sabahattin Gündüz, Nilüfer E Duran, Murat Biteker, Tahsin Güneysu, Tayyar Gökdeniz, Mehmet A Astarcioǧlu, Emre Ertürk, Ahmet Ç Aykan, Mustafa Yildiz, Mehmet Özkan
Journal: Circulation (2008)

Differentiation of pannus (P) and thrombus (THR) in prosthetic heart valve obstruction (PHVO) is still a confusive state at the present cardiological practise. Transesophageal echocardiography (TEE) is not fully capable method in this condition. We considered that cardiac 64-slice multidetector computerized tomography (MDCT) may have a value in the management of PHVO. Thirtytwo of 37 pts (22 male, mean age 47±11 years, 17 with atrial fibrillation) with PHVO (35 mitral, 2 tricuspid) were detected with TEE and also with MDCT before and after thrombolytic therapy (TT). Five pts having monoleaflet valves were excluded due to excessive artifacts. Pre-TT MDCT revealed at least 1 culprit mass (CM) which was considered to be the cause of PHVO and the Hounsfield unit (HU) values of CM’s were measured. All pts underwent TT under the guidance of serial TEE. The study consisted of 2 groups up to response of CM’s to TT demonstrated by post-TT MDCT. Group I: Successfully lysed CM’s, Group II: Nonresponder CM’s. TEE disclosed THR in 26 pts, however the cause of PHVO in 6 pts remained undefined. Pre-TT MDCT disclosed 45 distinct CM’s on 32 valves. Post-TT MDCT disclosed the number of CM’s for groups I and II: 26 and 19, respectively. Significant difference between mean HU values of groups was found [87 (range 11–180), 331 (range 168–510), respectively, p&lt;0.001]. A cut-off value of HU&gt;200 predicted nonresponder CM’s (sensitivity 94%, specificity 96%, p&lt;0.001). CM’s of 6 pts with undefined TEE findings were all in group II and pure P was demonstrated surgically. In group I, 17 of 26 (%65) CM’s were completely and the remaining partially lysed which was confirmed by TEE. A cut-off value of HU&lt;100 predicted complete lysis (sensitivity 100%, specificity %95, p&lt;0.001). Subgroup analysis of CM’s with HU=100–200 revealed 10% completely and 80% partially lysis and 10% remained unresponded as confirmed by TEE. MDCT can be a useful technique for evaluation of PHVO caused by THR or P formation. Higher HU values denote P whereas the lower values THR. MDCT can also predict the response to TT. The higher the HU value the less the successful outcome. The CM’s with HU&gt;200 are almost always resistant to TT.
Continuing education in psychiatry for physicians. Report of a four-year experience
Authors: L. F. Rittelmeyer
Journal: JAMA (1972)

The Department of Psychiatry of Georgetown University School of Medicine has conducted a postgraduate program for physicians in the area of Washington, DC, for four years. Forty-eight nonpsychiatrist practitioners have participated in one or more 12-week series of seminars designed to improve their ability to treat patients with emotional disorders. Problems were encountered in recruitment, program development, and faculty participation. The seminars assisted participants in modifying attitudes about emotionally disturbed patients and increased their knowledge and skills in dealing with them. All of the physicians who participated for three or more years demonstrated improved attitudes and broadened the scope or style of their practices in the management of emotional problems.
Totally neoadjuvant chemoradiation therapy with mFOLFOX6 in locally advanced rectal cancer: A single-arm phase II study (FOTAC).
Authors: Yanhong Deng, Jianwei Zhang, Yue Cai, Huabin Hu, Jian Xiao
Journal: Journal of Clinical Oncology (2018)

732 Background: In our previous FOWARC study, in the group of preoperative systemic chemotherapy with mFOLFOX6 combined with radiation, the pCR rate was up to 27.5%. In another study, adding mFOLFOX6 after neoadjuvant chemo radiation in locally advanced rectal cancer improve the pCR rate to 38%. This phase II study aimed to explore whether totally neoadjuvant chemoradiation therapy with mFOLFOX6 could further improve the pCR rate in locally advanced rectal cancer. Methods: Patients with fixed cT3 or cT4 rectal cancer evaluated by pelvic MRI participated in this trial. All candidates were to receive long term radiation for 25 times and 50Gy before surgery. Four cycles of mFOLFOX6 would be performed every 2 weeks during radiotherapy, and another 4-6 cycles would be added after radiotherapy and before TME. Totally, the patients will receive 6-8 cycles of chemotherapy before surgery. The primary endpoint is the pathologic complete response rate (pCR).The secondary endpoint included 3-year disease free survival rate, 3-year local recurrence rate, and safety. Results: Between April 2016 and May 2017, 81 patients were enrolled and 79 participants had received TME. Two patients required watch and wait, because the tumor location is too low to perform sphincter-preserving operation. Of 79 patients completing chemoradiotherapy and adding chemotherapy before surgery, 32.9% (26/79) of patients achieving pCR, and 54.4% (43/79) of patients had tumor downstaging to ypstage 0-I. Among patients who received 8 cycles of chemotherapy before surgery and the interval was more than 10 weeks between radiotherapy and operation, the pCR was 45.2%. Conclusions: Totally neoadjuvant chemoradiotherapy greatly improve the pCR rate and tumor downstaging rate. Clinical trial information: NCT02887313.
Aromatici e Nervini. Nell'Aliemtazione. I Condimenti, L'alcool (Vino, Birra, Liquori, Rosolii, ecc.); Il Caffè; Il Thè; Il Guarana; La Noce Di Kola, ecc. Sull'Uso Del Tabacco da Fuma e da Fiuto.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical teaching and the private patient
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE STRUGGLE TO RECLAIM STATE INSTITUTIONS FROM POLITICAL EXPLOITATION.
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Promising agents for limiting renal damage
Authors: E. Blume
Journal: JAMA (1983)

Calcium entry blockers may be able to prevent acute renal injury from causing permanent kidney damage. Speaking at a National Kidney Foundation symposium held recently in Washington, DC, Thomas J. Burke, MD, associate professor of medicine and physiology at the University of Colorado School of Medicine, Denver, described studies in which he and colleagues used the intravenous drug verapamil to protect dog kidneys against long-term damage after ischemic insult. Verapamil blocks entry of calcium into cells and is used primarily to stabilize cardiac function. High levels of intracellular calcium, which develop during ischemic insult, block adenosine triphosphate production, leading to cell death. Burke reasoned that if excess calcium could be prevented from entering kidney cells during periods of renal ischemia, permanent tissue damage might be averted. To test this hypothesis, Burke and associates Robert Schreier, MD, Joel Gordon, MD, and Patricia Arnold treated (via a renal artery) single kidneys of
Male reproductive toxicology: comparison of the human to animal models.
Authors: P K Working
Journal: Environmental Health Perspectives (1988)

The human male is of relatively low fertility and thus may be at greater risk from reproductive toxicants than are males of the common laboratory animal model species. Lack of knowledge of the physiological differences that contribute to interspecies variation between man and animals can prevent the effective application of animal data to the assessment of human reproductive risk. Evaluation of spermatogenesis from testicular histology, while uncommon, can provide valuable information about human reproductive risk. The measurement of sperm count or concentration has long been the most feasible approach for human semen evaluation, but may be an insensitive indicator of reproductive function because of high sample-to-sample variability. Interspecies extrapolation factors can be calculated by comparing the reduction in sperm count in humans and test species after exposure to drugs or chemicals. These factors can provide a realistic assessment of relative risk, provided that the sperm are counted at the appropriate time after exposure. However, the degree to which extrapolation factors derived for one agent, and only from sperm counts, can be generalized is not known. Monitoring of sperm motility and morphology parameters is also a common means of evaluating human semen quality, but these techniques are also hampered by the relatively high interindividual and intersample variability. Computer-assisted and morphometric approaches show promise of decreasing the subjective nature of these evaluations and increasing their value in risk assessment procedures. Improvements in predicting human reproductive risk can be expected to come from increased knowledge about reproductive mechanisms in man and animals, together with the utilization of objective measures of cellular indicators of male reproductive function.
Index of Subjects&lt;subtitle&gt;Volume 23 July 1959 • December 1959&lt;/subtitle&gt;
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Index of Subjects: Volume 23 July 1959 • December 1959 Get access JNCI: Journal of the National Cancer Institute, Volume 23, Issue 6, December 1959, Pages 1489–1495, https://doi.org/10.1093/jnci/23.6.1489 Published: 01 December 1959
Surgery
Authors: C. H. Organ
Journal: JAMA (1991)

Of all the research and clinical accomplishments from our surgical laboratories and hospitals over the last year, we have chosen to concentrate on the molecular biology of cancer, the surgical control of hyperlipidemias, extracorporeal membrane oxygenation, fetal surgery, lung transplantation, and laparoscopic surgery. Current efforts in molecular biology are primarily directed at understanding genetic alterations relating to neoplasia, in hopes of improving diagnosis, prognosis, and therapy. For example, the deletion of the Rb gene has been found to be associated with retinoblastoma development, and the nature and function of the protein encoded by the gene have been identified. Colorectal cancer provides an excellent model for current theories of cancer development, which suggest that multiple genetic alterations must occur to allow normal cell transformation to malignancy. Multiple genetic alterations, such as deletions of chromosomes 5, 17, and 18,<sup>1</sup>can be demonstrated in up to 70% of colorectal cancers.<sup>2</sup>These
Endometrial Carcinoma
Authors: Antonio Di Cristofano, Lora Hedrick Ellenson
Journal: Annual Review of Pathology Mechanisms of Disease (2006)

Endometrial carcinoma, a common malignancy of the female genital tract, is composed of a number of tumor types with different light-microscopic features, molecular genetic alterations, and prognoses. In addition, hormonal influences significantly impact growth regulatory pathways and interact with genetic alterations in the pathogenesis of at least some types of endometrial carcinoma. These factors have complicated the analyses of endometrial carcinoma, but over the past decades, awareness of the different types of endometrial carcinoma, in addition to careful clinicopathological studies, molecular analyses, and animal studies of the biological underpinnings of the different tumor types, has increased. We present the current understanding of endometrial carcinoma, from a molecular vantage point, highlighting what are presently thought to be the fundamental pathways involved in the development and progression of the major types of endometrial carcinoma.
Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM)
Authors: Laura Rosiñol, Raquel Jiménez-Segura, Ana Isabel Teruel, Javier De La Rubia, Maria Victoria Mateos, Miguel T. Hernandez, Dolores Hernández, M Jesús Blanchard, Belén Iñigo, Luis Palomera, Isabel Krsnik, Jose Francisco Tomas, Norma C. Gutiérrez, Jesús F. San Miguel, Juan José Lahuerta, Joan Blade
Journal: Blood (2013)
Digest
Authors: R. Spiller
Journal: Gut (2003)

A 21-year-old woman arrived at the emergency department with dyspnoea, arterial hypotension and abdominal pain after 5 days with a influenza-like syndrome. SARS-CoV-2 was detected by reverse transcription PCR in a nasopharyngeal swab specimen. CT of the chest and abdomen with contrast demonstrated a minimal amount of free intraperitoneal fluid, gallbladder with wall oedema, multiple para-aortic lymph node and interlobular septal thickening with ground glass opacities on the lungs. No pleural effusion or thromboembolism. Early broad-spectrum antibiotics, high-flow nasal cannula and norepinephrine were started. She was successfully treated with intravenous immunoglobulin and pulse corticosteroid therapy with methylprednisolone. The patient was discharged home with complete resolution of her symptoms and returned to her previous health status.